Altamont Looks to Medical Devices

Altamont Capital Partners has added Sharon Luboff to its team as an operating partner. Ms. Luboff and John Barr, also an operating partner at Altamont, have been tasked with acquiring and building a new medical device platform.

Ms. Luboff has 37 years of experience in the medical device industry. Most recently she was as a group vice president at C.R. Bard, a New Jersey-based developer and manufacturer of vascular, urology, oncology, and surgical medical devices, that was acquired by Becton Dickinson in 2017.  At Bard, she had corporate-wide responsibility for business development and strategy and she led more than 20 transactions for the company. Prior to joining Bard, she spent over 20 years at Baxter Healthcare in a variety of senior management positions. Ms. Luboff has her MBA and undergraduate degrees from Northwestern University.

“We are excited to capitalize on the compelling industry trends in the medical device segment, and this partnership positions us well to evaluate and pursue a wide range of assets,” said Casey Lynch, a managing director at Altamont. “Sharon’s demonstrated ability to lead and grow strong device businesses is an incredible asset to the firm.”

“I am excited to formalize my relationship with the Altamont team,” said Ms. Luboff. “Altamont’s business building orientation and successful track record around both corporate carveouts and founder/family transitions makes the firm the perfect partner. I am confident there are many opportunities to invest capital in the medical device sector that will benefit from our combined skills and experience.”

“We have developed a strong relationship with Sharon over time and have been consistently impressed with her industry expertise, strategic insights and track record of both operational and M&A success,” said Melissa Francis, a principal at Altamont. “We are thrilled to welcome her to the team. The partnership between Sharon and John, and their combined depth and breadth of experience, will enable us to pursue a wide range of opportunities in the medical device sector.”

Like Ms. Luboff, Mr. Barr has spent his entire career in the medical device sector. He joined Altamont in 2018 and from 2014 to 2017 he was the CEO of Surgical Specialties, a Boston-based medical device company specializing in sutures and surgical instruments. Earlier in his career, he served as president of Bausch & Lomb’s ophthalmic surgical products group. Bausch & Lomb was acquired by Valeant Pharmaceuticals in 2013.

Altamont invests equity of $15 million to $100 million in companies that have up to $50 million of EBITDA. Sectors of interest include business services; consumer; financial services; healthcare; industrial; retail, restaurants, and franchising; and technology.  The firm was formed in 2010 by Jesse Rogers, Randall Eason and Keoni Schwartz who previously worked together at Golden Gate Capital and Bain & Company. The firm has $2.5 billion of capital under management and is based in Palo Alto, CA (www.altamontcapital.com).

© 2019 Private Equity Professional | July 25, 2019

Print Friendly, PDF & Email

Related Articles

H.I.G. Expands Leadership Team H.I.G. Capital has expanded its leadership team with the promotion of Rick Rosen and Brian Schwartz to Co-President, a newly created title. Messrs....
Revelstoke Closes Fund II Revelstoke Capital Partners has held a final closing of Revelstoke Capital Partners Fund II LP (RCP Fund II) and Revelstoke Single Asset Fund I LP (RS...
Dyal Closes Largest Minority Fund Ever Raised Dyal Capital Partners, a division of Neuberger Berman, has held a final closing of Dyal Capital Partners IV LP (Fund IV) with over $9 billion of commi...
Raymond James Expands Financial Sponsors Team Raymond James has added Edward Lee as a managing director to the firm’s financial sponsors investment banking practice. Mr. Lee will be based in New Y...
Still the Same Generally favorable market conditions for private business sellers continued to prevail in the third quarter, according to GF Data’s just-released Nov...
Cortec’s Seventh Fund is “One and Done”... Cortec Group has held a first and final closing of its seventh institutional private equity fund, Cortec Group Fund VII LP, at its hard cap of $2 bill...